AbbVie Inc. (ABBV) is an American publicly traded biopharmaceutical company that develops and markets advanced therapies addressing some of the world's most complex and serious diseases. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has a diverse portfolio that includes treatments for conditions like rheumatoid arthritis, psoriasis, Crohn's disease and HIV, among others. The company's headquarters are in North Chicago, Illinois.
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. They aim to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
AbbVie is perhaps best known for its blockbuster drug, Humira (adalimumab), which is used for treating autoimmune diseases. Since its FDA approval in 2002, Humira has become one of the world's best-selling drugs, generating revenue of over $10 billion annually for AbbVie.
AbbVie's commitment to innovation is demonstrated by their investment in research and development. The company invests nearly half of its net revenues in their R&D program each year, reflecting the emphasis they put on creating new solutions and improving existing treatments for serious health conditions. The company's robust pipeline includes programs in the areas of oncology, immunology, neuroscience, and virology.
In 2020, AbbVie completed a $63 billion acquisition of Allergan, a pharmaceutical company that manufactures popular products such as Botox. This acquisition expanded AbbVie's business model beyond reliance on individual products like Humira, and diversified its revenue streams.
AbbVie takes corporate responsibility seriously and runs numerous initiatives aiming at promoting sustainable practices. The company has set targets in areas like energy usage, reduction of greenhouse gas emissions, and waste to landfill, and has launched the STEM for Girls initiative, aimed at encouraging girls to pursue interest and studies in science, technology, engineering, and math.
The company's stock, which trades under the ticker symbol 'ABBV' on the New York Stock Exchange, offers an attractive option for investors due to its strong performance, as well as its commitment to a reliable dividend payout.
In conclusion, with its extensive and diverse portfolio of healthcare solutions, investments in research and development, and commitment to corporate responsibility, AbbVie Inc. is a global leader in the biopharmaceutical industry.